10-Q: Ludwig Enterprises Reports Q1 2025 Results: Net Loss Decreases Amidst Efforts to Launch New Products

Ludwig Enterprises, Inc. reports a decreased net loss for Q1 2025 compared to Q1 2024, as it prepares to launch new products and manages its debt obligations.

Summary

• Ludwig Enterprises, Inc. reported its financial results for the quarter ended March 31, 2025.
• The company is focused on developing products and services in the healthcare industry using cutting-edge technologies.
• The company had no revenues for the three months ended March 31, 2025, compared to $10 in revenue for the same period in 2024.
• The net loss for the quarter was $540,943, a decrease from the $1,610,880 net loss in the same period last year.
• Operating expenses increased to $524,921 from $365,589 in the prior year, driven by sales and marketing activities.
• Research and development expenses were $74,234, compared to $0 in the prior year.
• The company had a working capital deficit of $2,752,716 as of March 31, 2025.
• Cash on hand was $16,571 as of March 31, 2025.
• The company is seeking to raise debt or equity-based capital to meet its obligations.
• Management plans to execute business operations more fully, seek strategic acquisitions, and explore partnership opportunities.
• The company issued 1,057,000 shares of common stock for marketing services valued at $166,372.
• Subsequent to the quarter, the company extended the maturity dates on some notes and entered into new securities purchase agreements for $625,000.
• The company's disclosure controls and procedures over financial reporting were deemed not effective as of March 31, 2025.

Sentiment

Score: 4

Explanation: The sentiment is slightly negative due to the lack of revenue, significant working capital deficit, and going concern uncertainty, although the reduced net loss and efforts to secure funding provide some optimism.

Positives

• The net loss decreased significantly from $1,610,880 in Q1 2024 to $540,943 in Q1 2025.
• The company is actively preparing to launch its products, as evidenced by increased sales and marketing expenses.
• Research and development activities are underway, indicating progress in product development.
• The company is actively seeking additional capital through debt and equity financing.

Negatives

• The company had no revenues for the three months ended March 31, 2025.
• The company has a significant working capital deficit of $2,752,716.
• The company's cash on hand is very low at $16,571.
• The company's disclosure controls and procedures over financial reporting were deemed not effective as of March 31, 2025.

Risks

• The company's ability to continue as a going concern is in doubt due to its working capital deficit and net losses.
• The company's success depends on its ability to raise additional capital.
• The company faces risks associated with the development and commercialization of new products.
• The company's disclosure controls and procedures are not effective, which could lead to errors in financial reporting.
• The company's stock price could be volatile.

Future Outlook

The company expects revenues from sales of planned products to begin during the third quarter of 2025 and anticipates that operating expenses for all of 2025 will exceed those incurred during the year ended December 31, 2024, assuming they can obtain needed capital.

Management Comments

• Management's strategic plans include executing business operations more fully during the year ended December 31, 2025, seeking strategic acquisitions of health care technology, and exploring prospective partnership opportunities.

Industry Context

The company is positioning itself at the forefront of a new era of medicine with the development of products that will embody proprietary mRNA genomic technology for detecting genetic biomarkers for inflammatory driven diseases.

Comparison to Industry Standards

• It is difficult to compare Ludwig Enterprises to industry standards due to its early stage and lack of revenue.
• Many comparable companies are private or are divisions of larger companies.
• Without specific details on the technology and target market, a detailed comparison is not possible.

Related Party Transactions

• In December 2024, the Company issued a Promissory Note to our former chief executive officer (CEO) in the principal amount of $5,000.
• On March 10, 2025, the Company issued a Promissory Note to our chief executive officer (CEO) in the principal amount of $36,912.
• For the three months ended March 31, 2025, our CEO paid operating expense of $15,247 on behalf of the Company.

Stakeholder Impact

• Shareholders face the risk of dilution if the company issues more shares to raise capital.
• Employees' job security is uncertain due to the company's going concern risk.
• Customers may be impacted by delays in product development or commercialization.
• Suppliers and creditors face the risk of non-payment if the company is unable to raise sufficient capital.

Next Steps

• Execute business operations more fully during the year ended December 31, 2025.
• Seek out strategic acquisitions of health care technology.
• Explore prospective partnership opportunities.
• Obtain additional debt or equity-based capital from third parties to implement full business plans.

Key Dates

Keywords

financial results, mRNA, healthcare, net loss, operating expenses, research and development, working capital, going concern, convertible notes, common stock, biomarkers, inflammation